Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
  • LinkedIn
  • Instagram
OtherPractice

Biotin interference

Underrecognized patient safety risk in laboratory testing

Jessica L. Gifford, S.M. Hossein Sadrzadeh and Christopher Naugler
Canadian Family Physician May 2018; 64 (5) 370;
Jessica L. Gifford
Clinical biochemistry fellow in the Clinical Biochemistry Section for Calgary Laboratory Services and in the Department of Pathology and Laboratory Medicine at the University of Calgary in Alberta.
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S.M. Hossein Sadrzadeh
Chief of the Clinical Biochemistry Section for Calgary Laboratory Services and Clinical Professor in the Department of Pathology and Laboratory Medicine at the University of Calgary.
PhD DABCC FACB
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher Naugler
Associate Professor and Head of the Department of Pathology and Laboratory Medicine at the University of Calgary and Calgary Laboratory Services.
MD MSc FCFP FRCPC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • eLetters
  • Info & Metrics
  • PDF
Loading

Dietary supplementation with biotin is increasingly recognized as a patient safety risk, as it might lead to incorrect results for various common laboratory tests. Biotin (also known as vitamin H, vitamin B7, and coenzyme R) is a water-soluble vitamin that acts as an enzyme cofactor in fatty acid biosynthesis, the citric acid cycle, and metabolism of odd-numbered fatty acids and branched-chain amino acids. It has additional roles in gluconeogenesis and gene expression. In the diet, biotin is bound to proteins found in organ meats, such as liver, kidney, and pancreas, as well as in eggs, yeast, and milk. Cereal grains, fruits, most vegetables, and muscle meat are poor sources of biotin. In Western populations, dietary biotin intake is estimated to be 35 to 70 µg daily, a level in line with the recommended dietary allowance. Most multivitamin pills contain about 30 µg of biotin. High-dose supplementation (doses greater than 1 mg/d) plays a role in therapy for several diseases, including biotinidase deficiency, mitochondrial metabolic disorders, and multiple sclerosis.1 Doses up to 10 mg a day are frequently encountered in nutritional supplements taken to improve hair, skin, and nail health.

The problem is that many common blood tests employ a biotin-streptavidin reaction as part of the test procedure. While the amount of usual dietary biotin intake is not expected to be high enough to affect these tests, biotin supplementation at doses greater than 1 mg per day can cause either falsely low or falsely high test results, depending on the analyte and platform used for testing.

Biotin interference is particularly dangerous for patients in emergency situations who do not know they are taking high doses of biotin or when the treating physician does not know the patient is taking high doses. A literature search revealed an increasing number of published cases, most describing the problem of biotin interference in thyroid function tests.2 High-dose biotin can produce a dangerous combination of positive and negative interference among the thyroid tests (free thyroxine, free triiodothyronine, thyroid-stimulating hormone, and thyroid-stimulating hormone receptor antibodies) and paint a picture of Graves disease in patients who have either no clinical symptoms or unrelated symptoms. Without good clinical observations, this could lead to unnecessary procedures and treatments. Interference of high-dose biotin with thyroid tests is particularly troubling for patients with multiple sclerosis, as large doses of this vitamin are emerging as a new treatment.3 Interference with parathyroid hormone, follicle-stimulating hormone, luteinizing hormone, sex-hormone binding globulin, estradiol, progesterone, testosterone, cortisol, folate, vitamin B12, and ferritin testing has also been reported.2

The list of affected immunoassays varies for each analytic platform, and for a given test the manufacturer-supplied product information must be consulted to determine if biotin is an interferent. For some platforms, the list is extensive and includes the aforementioned tests, as well as those for cardiac function, β–human chorionic gonadotropin, and cancer biomarkers.4 In many of these immunoassays, biotin was an established interferent, but at doses thought to be rarely encountered in the general population. While manufacturers are aware of the increasing use of high-dose biotin and its potential effects on patient care, they have not, to date, suggested any concrete solutions beyond having patients abstain from this vitamin. Solutions proposed by local clinical laboratories include diluting the specimen with a validated assay diluent, running specimens on a different platform known to be unaffected by biotin, and using streptavidin-agarose beads to remove the biotin before the sample is run on the affected analyzer.5 All of these solutions will increase the costs associated with testing and highlight the potential financial implications of high-dose biotin on the health care system.

Interference of high-dose biotin on immunoassays in the clinical laboratory is an emerging issue. Many questions have not been addressed. What is the prevalence of high-dose biotin in a given patient population? What are the pharmacokinetics of high-dose biotin? How effective is the use of streptavidin-agarose beads to remove biotin interference? For many laboratories, the current solution is basic: It is recommended that patients abstain from taking biotin for at least 48 hours before specimen collection. The most effective approach, however, is an extensive communication campaign to educate physicians and patients.

Footnotes

  • Competing interests

    None declared

  • This article has been peer reviewed.

  • Copyright© the College of Family Physicians of Canada

References

  1. 1.↵
    1. Tourbah A,
    2. Lebrun-Frenay C,
    3. Edan G,
    4. Clanet M,
    5. Papeix C,
    6. Vukusic S,
    7. et al
    . MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: a randomised, double-blind, placebo-controlled study. Mult Scler 2016;22(13):1719-31. Epub 2016 Sep 1.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Elston MS,
    2. Sehgal S,
    3. Du Toit S,
    4. Yarndley T,
    5. Conaglen JV
    . Factitious Graves’ disease due to biotin immunoassay interference—a case and review of the literature. J Clin Endocrinol Metab 2016;101(9):3251-5.
    OpenUrlPubMed
  3. 3.↵
    1. Siddiqui U,
    2. Egnor E,
    3. Sloane JA
    . Biotin supplementation in MS clinically valuable but can alter multiple blood test results. Mult Scler 2017;23(4):619-20. Epub 2016 Dec 7.
    OpenUrl
  4. 4.↵
    1. Piketty ML,
    2. Polak M,
    3. Flechtner I,
    4. Gonzales-Briceño L,
    5. Souberbielle JC
    . False biochemical diagnosis of hyperthyroidism in streptavidin-biotin-based immunoassays: the problem of biotin intake and related interferences. Clin Chem Lab Med 2017;55(6):780-8.
    OpenUrl
  5. 5.↵
    1. Piketty ML,
    2. Prie D,
    3. Sedel F,
    4. Bernard D,
    5. Hercend C,
    6. Chanson,
    7. et al
    . High-dose biotin therapy leading to false biochemical endocrine profiles: validation of a simple method to overcome biotin interference. Clin Chem Lab Med 2017;55(6):817-25.
    OpenUrl
PreviousNext
Back to top

In this issue

Canadian Family Physician: 64 (5)
Canadian Family Physician
Vol. 64, Issue 5
1 May 2018
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Biotin interference
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Biotin interference
Jessica L. Gifford, S.M. Hossein Sadrzadeh, Christopher Naugler
Canadian Family Physician May 2018, 64 (5) 370;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Biotin interference
Jessica L. Gifford, S.M. Hossein Sadrzadeh, Christopher Naugler
Canadian Family Physician May 2018, 64 (5) 370;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Footnotes
    • References
  • eLetters
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Practice

  • Managing type 2 diabetes in primary care during COVID-19
  • Effectiveness of dermoscopy in skin cancer diagnosis
  • Spontaneous pneumothorax in children
Show more Practice

Praxis

  • Éponge à haut rebond comme outil de simulation d’une suture périnéale
  • High-rebound sponge as a simulation tool for perineal suture
  • Assessment and management of disability due to mental disorders
Show more Praxis

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • LinkedIn
  • Instagram
  • RSS Feeds

Copyright © 2025 by The College of Family Physicians of Canada

Powered by HighWire